Cambridge Investment Research Advisors, Inc. Guardant Health, Inc. Transaction History

Cambridge Investment Research Advisors, Inc.

$29.6 Billion
Q1 2025

A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Guardant Health, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 12,554 shares of GH stock, worth $465,627. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,554

Previous 16,597 24.36%

Holding current value

$465,627

Previous $507,000 5.52%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 22, 2025	SELL	$31.77 - $49.94 $128,446 - $201,907	-4,043 Reduced 24.36%	12,554 $535,000
Q4 2024 Feb 14, 2025	BUY	$20.2 - $38.11 $136,733 - $257,966	6,769 Added 68.87%	16,597 $507,000
Q3 2024 Oct 28, 2024	BUY	$22.3 - $36.29 $914 - $1,487	41 Added 0.42%	9,828 $225,000
Q2 2024 Jul 26, 2024	SELL	$16.07 - $31.84 $268,240 - $531,473	-16,692 Reduced 63.04%	9,787 $283,000
Q1 2024 Apr 24, 2024	BUY	$17.13 - $26.91 $28,110 - $44,159	1,641 Added 6.61%	26,479 $546,000
Q4 2023 Feb 09, 2024	SELL	$21.58 - $29.5 $18,256 - $24,957	-846 Reduced 3.29%	24,838 $672,000
Q3 2023 Oct 24, 2023	BUY	$25.8 - $39.97 $296,648 - $459,575	11,498 Added 81.05%	25,684 $761,000
Q2 2023 Jul 13, 2023	SELL	$20.94 - $38.01 $8,229 - $14,937	-393 Reduced 2.7%	14,186 $508,000
Q1 2023 May 11, 2023	BUY	$22.92 - $33.76 $148,154 - $218,224	6,464 Added 79.65%	14,579 $342,000
Q4 2022 Feb 08, 2023	BUY	$25.44 - $59.78 $52,762 - $123,983	2,074 Added 34.33%	8,115 $221,000
Q3 2022 Oct 17, 2022	BUY	$43.66 - $61.0 $263,750 - $368,501	6,041 New	6,041 $325,000
Q1 2022 May 12, 2022	SELL	$48.25 - $100.49 $137,995 - $287,401	-2,860 Closed	0 $0
Q4 2021 Feb 03, 2022	SELL	$88.71 - $120.43 $178,661 - $242,546	-2,014 Reduced 41.32%	2,860 $286,000
Q3 2021 Nov 02, 2021	BUY	$98.77 - $132.17 $13,432 - $17,975	136 Added 2.87%	4,874 $609,000
Q2 2021 Aug 10, 2021	SELL	$109.77 - $165.68 $392,317 - $592,140	-3,574 Reduced 43.0%	4,738 $588,000
Q1 2021 May 07, 2021	SELL	$127.04 - $179.1 $983,416 - $1.39 Million	-7,741 Reduced 48.22%	8,312 $1.27 Million
Q4 2020 Feb 04, 2021	BUY	$99.96 - $135.93 $763,594 - $1.04 Million	7,639 Added 90.79%	16,053 $2.07 Million
Q3 2020 Oct 29, 2020	BUY	$80.32 - $111.8 $218,470 - $304,096	2,720 Added 47.77%	8,414 $940,000
Q2 2020 Jul 27, 2020	BUY	$60.49 - $97.5 $43,855 - $70,687	725 Added 14.59%	5,694 $461,000
Q1 2020 May 08, 2020	SELL	$59.04 - $88.81 $3,424 - $5,150	-58 Reduced 1.15%	4,969 $345,000
Q4 2019 Feb 04, 2020	BUY	$59.49 - $82.78 $47,948 - $66,720	806 Added 19.1%	5,027 $392,000
Q3 2019 Nov 06, 2019	SELL	$62.59 - $110.3 $106,590 - $187,840	-1,703 Reduced 28.75%	4,221 $269,000
Q3 2019 Oct 28, 2019	BUY	$62.59 - $110.3 $370,783 - $653,417	5,924 New	5,924 $378,000
Q2 2019 Aug 15, 2019	SELL	$63.94 - $91.11 $196,295 - $279,707	-3,070 Closed	0 $0
Q1 2019 May 08, 2019	BUY	$34.3 - $97.98 $105,300 - $300,798	3,070 New	3,070 $0

Others Institutions Holding GH

# of Institutions

392

Shares Held

121M

Call Options Held

1.43M

Put Options Held

2.37M

View Full List

About Guardant Health, Inc.

Ticker GH
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 102,220,000
Market Cap $3.79B
Description
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...

More about GH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.

Account

Cambridge Investment Research Advisors, Inc. Guardant Health, Inc. Transaction History